IP Library › Granted Patent US 9,302,013
Granted Patent B2
US 9,302,013 · App. 13/982,492 · Granted Apr 5, 2016

Active principle for mitigating undesired medical conditions

Inventors: Tim Bowden (Uppsala, SE); Kristoffer Bergman (Stockholm, SE); Thomas Engstrand (Uppsala, SE); Lennart Soderberg (Uppsala, SE)
Assignee: TERMIRA AB
A61K47/48176A61K31/765A61K31/785A61K47/4823
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,302,013
App. No.
13/982,492
Granted
Apr 5, 2016
Kind
B2
Abstract

A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic center complying with the formula X 1 (—R″—)(—R′) m H n where: a) X 1 is a single-bonded heteroatom selected amongst N, O and S and exhibits a free electron pair; b) m is 0 or 1 and n is 1 or 2; c) —R″— is a bivalent organic group providing attachment to the carrier via one of its free valences and to X 1 at the other free valence; and d) R′— is a monovalent organic group attached to the X 1 via its free valence. A method for treating or preventing inflammatory-related conditions in an individual suffering from such conditions includes: providing the composition; and contacting the mediator within or separate from the individual.

Claims (16)

1. A composition for treating or preventing inflammatory-related conditions comprising an active principle (=AP) comprising a polyvinyl alcohol carrier which exhibits a plurality of a scavenger structure which is capable of mitigating and/or neutralising the activity of a mediator of inflammatory-related conditions, said scavenger structure comprising carbazate as a nucleophilic centre, said AP being attached to a support made of a material selected from the group consisting plastic, glass, metal, mineral, ceramic and polymeric material.

2. The composition of claim 1 , wherein,

the scavenger structure of the polyvinyl alcohol carrier further comprises b) a second nucleophilic centre which exhibits a single-bonded first heteroatom N, O or S (═Y 1 ) and complies with formula III

Y 1 (—R″—)(—R′) m H n   (formula III)

where:

a) Y 1 exhibits a free electron pair,

b) m is 0 or 1 and n is 1 or 2 with the sum of m plus n being 2 for Y 1 ═N and 1 for Y 1 ═S and O,

c) —R″— is a bivalent organic group providing attachment to the carrier via one of its free valences and direct attachment to the heteroatom Y 1 at the other one of its free valences, and

d) R′— is a monovalent organic group directly attached to the heteroatom Y 1 via its free valence; and

said first heteroatom Y 1 is capable of participating in an intramolecular addition reaction with a multiple bond formed when the carbazate is reacting with a keto or aldehyde carbon or a reactive multiple bond of an inflammatory related mediator.

3. The composition of claim 1 , wherein the support is made of a polymeric material selected from the group consisting of polysaccharides and polyester polymers.

4. The composition of claim 1 , wherein the AP is present in a concentration of 1 μg-100 mg/ml.

5. The composition of claim 1 , wherein the polyvinyl alcohol carrier has 200-600 monomeric units.

6. A composition for treating or preventing inflammatory-related conditions, comprising as an active principle (=AP) a polyvinyl alcohol carrier which exhibits a plurality of a scavenger structure which is capable of mitigating and/or neutralising the activity of a mediator of inflammatory-related conditions, said scavenger structure comprising carbazate as a nucleophilic centre, said polyvinyl alcohol being attached to polysaccharide support.

7. The composition of claim 6 , wherein the AP is present in a concentration of 1 μg-100 mg/ml.

8. The composition of claim 6 , wherein the polyvinyl alcohol carrier has 200-600 monomeric units.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2016
From: TERMIRA AB
To: PVAC MEDICAL TECHNOLOGIES LTD
Reel/Frame 040585/0337 →
MERGER Recorded Oct 21, 2015
From: IPR-SYSTEMS SWEDEN AB
To: TERMIRA AB
Reel/Frame 036841/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2013
From: BOWDEN, TIM; BERGMAN, KRISTOFFER; ENGSTRAND, THOMAS; SODERBERG, LENNART
To: IPR-SYSTEMS SWEDEN AB
Reel/Frame 031161/0429 →
Priority Claims (1)
SE 1100066 · Jan 31, 2011 · national
Continuity (2)
Provisional Application 61475425 · Apr 14, 2011
Related Publication 20130302268A1 · Nov 14, 2013